Revenue Update on Flexion Therapeutics Inc(NASDAQ:FLXN)

Flexion Therapeutics Inc(NASDAQ:FLXN) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Aug 3, 2016. Earnings per share were $-0.63. Analysts had estimated an EPS of $-0.67.

In a different note, BMO Capital said it Initiates Coverage on Flexion Therapeutics Inc, according to a research note issued on Jun 29, 2016. The shares have been rated ‘Outperform’ by the firm.

Flexion Therapeutics Inc (FLXN) made into the market gainers list on Fridays trading session with the shares advancing 1.98% or 0.34 points. Due to strong positive momentum, the stock ended at $17.5, which is also near the day’s high of $17.54. The stock began the session at $17.18 and the volume stood at 2,08,728 shares. The 52-week high of the shares is $29.09 and the 52 week low is $7.56. The company has a current market capitalization of $482 M and it has 2,75,21,070 shares in outstanding.

Several Insider Transactions has been reported to the SEC. On Jun 22, 2016, Samuel D Colella (director 10% owner) purchased 25,504 shares at $13.74 per share price.Also, On Jun 16, 2016, C Ann Merrifield (director) purchased 1,000 shares at $13.39 per share price.On May 23, 2016, Michael D. Clayman (CEO) purchased 2,000 shares at $10.40 per share price, according to the Form-4 filing with the securities and exchange commission.

Flexion Therapeutics Inc. is a specialty pharmaceutical company focused on the development and commercialization of injectable pain therapies. The Company is also focused on anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions such as osteoarthritis (OA) a type of degenerative arthritis. The Company’s portfolio of product candidates addresses the OA pain treatment spectrum from moderate to severe pain. The Company’s products include FX006 which is indicated for front line intra-articular (IA) therapy for patients with moderate to severe OA pain; FX007 which is indicated for post-operative pain and FX005 which is indicated for end-stage OA pain. The Company is conducting a pivotal Phase IIb clinical trial of FX006. The Company is conducting preclinical local pharmacology and toxicology experiments of FX007. FX005 has completed its Phase IIa trials.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *